首页> 美国卫生研究院文献>Science Advances >Red blood cell–derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy
【2h】

Red blood cell–derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy

机译:红细胞衍生的纳米红细胞体可增强癌症免疫疗法的抗原递送

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Erythrocytes or red blood cells (RBCs) represent a promising cell-mediated drug delivery platform due to their inherent biocompatibility. Here, we developed an antigen delivery system based on the nanoerythrosomes derived from RBCs, inspired by the splenic antigen-presenting cell targeting capacity of senescent RBCs. Tumor antigens were loaded onto the nanoerythrosomes by fusing tumor cell membrane–associated antigens with nanoerythrosomes. This tumor antigen–loaded nanoerythrosomes (nano-Ag@erythrosome) elicited antigen responses in vivo and, in combination with the anti–programmed death ligand 1 (PD-L1) blockade, inhibited the tumor growth in B16F10 and 4T1 tumor models. We also generated a tumor model showing that “personalized nano-Ag@erythrosomes” could be achieved by fusing RBCs and surgically removed tumors, which effectively reduced tumor recurrence and metastasis after surgery.
机译:由于其固有的生物相容性,红细胞或红细胞(RBC)代表了有前途的细胞介导的药物递送平台。在这里,我们开发了基于源自红细胞的纳米红细胞体的抗原递送系统,该系统受衰老RBC的脾脏抗原呈递细胞靶向能力的启发。通过将肿瘤细胞膜相关抗原与纳米红细胞融合在一起,将肿瘤抗原加载到纳米红细胞上。这种载有肿瘤抗原的纳米红细胞体(nano-Ag @ erythrosome)(nano-Ag @ erythrosome)在体内引起抗原反应,并与抗编程死亡配体1(PD-L1)阻滞相结合,抑制了B16F10和4T1肿瘤模型中的肿瘤生长。我们还生成了一个肿瘤模型,显示通过融合红细胞和手术切除的肿瘤可以实现“个性化的纳米Ag @红细胞体”,从而有效地减少了手术后的肿瘤复发和转移。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号